| |
VA researchers develop biomed innovations in all areas of healthcare, from substance abuse treatments to visual impairment aids and more. License and commercialize VA innovations with no-cost help from TechLink. Learn about available technologies. 
|
|
Today’s Big NewsJul 26, 2024 |
| By Nick Paul Taylor Bristol Myers Squibb had had a whiplash change of heart on its BCMA bispecific T-cell engager, halting further development months after filing to run a phase 3 trial. The Big Pharma disclosed the change of plan alongside a phase 3 win for a potential challenger to Regeneron, Sanofi and Takeda. |
|
|
|
By Nick Paul Taylor Calliditas Therapeutics’ slimmed-down, truncated and rethought primary biliary cholangitis drug has hit its primary endpoint. But the biotech, which changed the midphase trial to cut costs, only saw a positive trend on liver stiffness and reported a higher rate of treatment-related dropouts on the study drug. |
By James Waldron Acticor Biotech is discontinuing a phase 2/3 study of a blood thinner given alongside heart surgery based on the results of a futility analysis. |
Sponsored by CSafe Global How is the cold chain adapting to the cell and gene therapy boom? Emilio Frattaruolo, Vice President of Cell and Gene Therapies at CSafe, discusses the logistical challenges and innovations shaping the future of these revolutionary treatments. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More. 
|
|
By James Waldron Prioritizing the preclinical autoimmune programs means the company’s two IL-2-based cancer drugs—both of which have already made it into human trials—are being placed on the back burner. |
Sponsored by InMed Pharmaceuticals InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Gabrielle Masson,Darren Incorvaia Moderna’s board is undergoing major movement, including the departure of co-founder Robert Langer. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Ayla Ellison,Annalee Armstrong In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
By Fraiser Kansteiner Despite winning approvals in a range of countries like the U.S., China and Japan, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European regulators. |
By Darren Incorvaia Just over a month after announcing its new Clinical Data Studio, Medidata has its first big customer. Eisai announced July 25 it's incorporating Medidata’s data studio into its clinical trial management platform. |
By Nick Paul Taylor AbbVie could have the hottest cancer drug launch of 2025 on its hands. That is one takeaway from a recent ZoomRx survey, which found oncologists are more aware of and excited about AbbVie’s telisotuzumab-vedotin (Teliso-V) than any other investigational cancer candidate. |
By Angus Liu Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's ADC star Enhertu slowed down. Samsung Biologics' quarterly revenue crossed the 1 trillion South Korean won mark for the first time. And more. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
|
|---|
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
